Drug updated on 4/16/2024

Dosage FormTablet (oral; 20 mg)
Drug ClassSodium-glucose co-transporter 2 inhibitors
Ongoing and
Completed Studies


  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Bexagliflozin (Brenzavvy) is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It significantly reduces HbA1c levels, fasting plasma glucose levels, blood pressure, and body weight compared to placebo.
  • The information was derived from three systematic reviews/meta-analyses studies that provide a detailed overview of Brenzavvy's efficacy and safety profile for patients with type 2 diabetes mellitus.
  • In terms of side effects, bexagliflozin aligns closely with other sodium-glucose cotransporter-2 inhibitors. No significant differences were found in the occurrence of hypoglycemia or other common side effects when compared to placebo.
  • When comparing Brenzavvy's efficacy against other SGLT2 inhibitors regarding renal protection in patients with chronic kidney disease and T2DM, it showed favorable outcomes by reducing estimated glomerular filtration rate (eGFR) alongside dapagliflozin and empagliflozin.
  • However, while bexagliflozin had positive impacts on renal outcomes similar to luseogliflozin and dapagliflozin, empagliflozin, dapagliflozin, and canagliflozin stood out more significantly for their ability to reduce urine albumin creatinine ratio levels, indicating variances among different SGLT2 inhibitors' degree of renal protection.
  • While there are no specific subgroup considerations mentioned within these studies beyond those suffering from T2DM or chronic kidney disease, there seems implied benefit towards individuals having BMI >25 kg/m² who may notice more significant weight loss.